Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03802994 · ClinicalTrials.gov registry record · Early Phase 1
Pneumococcal Conjugate Vaccine in Aging Renal Transplant
A Early Phase 1 study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 57
- Enrollment target
NCT03802994: Clinical Trial Early Phase 1 study, sponsored by VA Office of Research and Development.
NCT03802994 is a Early Phase 1 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 57 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03802994, a Early Phase 1 study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
The goal of the research proposed in the current application is to first define how much antibody aging renal transplant and dialysis recipients make after they are vaccinated with the pneumonia vaccine and how this compares to similar aged persons with good renal function and healthy young adults. The investigators will study differences in the kind of B cells and markers on the B cells that are known to be important in the response to the pneumonia vaccine in aging renal transplant and aging dialysis recipients compared to similarly aged and young healthy controls. Finally, the investigators will study how safe the pneumonia vaccine is in aging renal transplants. The answers to these questions will help in designing a better vaccine for older people with a renal transplant or on dialysis.
Interventions
- OTHER Peripheral blood sample
- BIOLOGICAL 13 valent conjugated pneumococcal vaccine
- DRUG 23 valent pneumococcal polysaccharide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2020-02-28 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03802994
The ClinicalTrials.gov registry entry for NCT03802994 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Peripheral blood sample is the first listed.
NCT03802994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03802994 about?
NCT03802994 is a clinical study titled "Pneumococcal Conjugate Vaccine in Aging Renal Transplant". The goal of the research proposed in the current application is to first define how much antibody aging renal transplant and dialysis recipients make after they are vaccinated with the pneumonia vaccine and how this compares to similar aged persons with good renal function and healthy young adults. ...
What is the current status of trial NCT03802994?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 57 participants. The study started on 2018-11-01. Estimated completion is 2020-02-28.
What interventions are being tested in trial NCT03802994?
The interventions under investigation include: Peripheral blood sample (OTHER), 13 valent conjugated pneumococcal vaccine (BIOLOGICAL), 23 valent pneumococcal polysaccharide vaccine (DRUG).
Who is sponsoring clinical trial NCT03802994?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.